Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

Ashida, Kiyoshi; Sakurai, Yuuichi; Nishimura, Akira; Kudou, Kentarou; Hiramatsu, Naoki; Umegaki, Eiji; Iwakiri, Katsuhiko; Chiba, Tsutomu

doi:10.1111/apt.13331

Cited by 146 publications

(202 citation statements)

References 32 publications

Supporting

Mentioning

192

Contrasting

Order By: Relevance

“…A dose of 40 mg was selected as the therapeutic dose for this study because in a previous phase II study,10 40 mg was the maximum dose used and doses ≥20 mg were expected to be used for different indications. The supratherapeutic dose in this study was 120 mg because it was the highest dose administered in healthy subjects in a phase I study4 and was well tolerated.…”

Section: Methodsmentioning

confidence: 99%

“…Electrocardiogram (ECG) parameters for vonoprazan in clinical trials have not shown any clinically meaningful QT/QTc prolongation 4, 5, 9, 10, 11, 12, 13, 14. Despite the lack of cardiac arrhythmic events in the extensive clinical development program, a thorough QT study was conducted to provide a definitive assessment of the effects of vonoprazan on the QT interval.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects

Astruc

Jenkins

2017

Clinical Translational Sci

View full text Add to dashboard Cite

This phase I, randomized, 4‐period, 4‐sequence, double‐blind, active‐ and placebo‐controlled, crossover study assessed the effects of vonoprazan on the QT/QTc interval in healthy subjects. Subjects received single oral doses of vonoprazan 40 mg, vonoprazan 120 mg, moxifloxacin 400 mg (positive control/open label), and placebo. The primary end point was time‐matched, placebo‐corrected, baseline‐adjusted mean Fridericia‐corrected QT interval (ddQTcF). Of 64 subjects (mean age, 37.8 years; 50% male), 63 received all four regimens. One subject discontinued due to nondrug‐related adverse event of tonsillitis. Assay sensitivity was established; lower bound of the one‐sided 95% confidence interval (CI) for ddQTcF was >5 ms between 1.5 and 12 h following moxifloxacin administration. For both doses of vonoprazan, the one‐sided upper 95% CI ddQTcF did not exceed 10 ms. There was no correlation between plasma vonoprazan concentrations and increases in ddQTcF. Vonoprazan was well tolerated. No severe adverse events/deaths were reported. (European Clinical Trials Database Registry: 2011‐004003‐20.)

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects

Astruc

Jenkins

2017

Clinical Translational Sci

View full text Add to dashboard Cite

show abstract

“…Characteristics of vonoprazan are the rapid onset, high potency, and long duration of its acid secretion-inhibitory effect 25,26 . Excellent results have also been reported by its clinical trials against reflux esophagitis 28,29 . However, there is also concern over adverse effects associated with its strong acid-suppressive effect.…”

Section: -4) Switching To Vonoprazanmentioning

confidence: 80%

Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis

Iwakiri

2017

J Nippon Med Sch

View full text Add to dashboard Cite

“…In addition, the intragastric pH following VPZ treatment (pH 5.2) has been identified to be significantly higher than that following esomeprazole treatment (pH 3.0) on day 1 of therapy (18). The superior efficacy of VPZ compared with PPIs has been reported in various gastrointestinal diseases (19)(20)(21)(22).…”

Section: Eradication Rate % (N) -------------------------------------mentioning

confidence: 99%

Second‑line triple therapy in failures with vonoprazan‑based triple therapy for eradication of Helicobacter pylori

et al. 2018

View full text Add to dashboard Cite

Abstract. Gastric acid inhibition during treatment is important for the eradication of Helicobacter pylori (H. pylori) infection. A novel potassium-competitive acid blocker, vonoprazan (VPZ), has been demonstrated to achieve high eradication rates; however, the efficacy of second-line treatment in failures of VPZ-based triple therapy has not been well studied.The aim of the current study was to determine the efficacy of VPZ in a first-line regimen for H. pylori eradication, and the efficacy of a second-line regimen using metronidazole (MTZ) in failures with the first-line regimen. Of 580 subjects enrolled in the study, 524 patients completed first-line treatment (275 patients who received VPZ and 249 patients who received LPZ). First-line regimens consisted of a combination of clarithromycin (CAM) 200 or 400 mg twice a day, amoxicillin (AMPC) 750 mg twice a day, and either LPZ 30 mg or VPZ 20 mg twice a day, administered orally for 7 days. CAM and VPZ/LPZ were replaced with metronidazole (MTZ) 250 mg and rabeprazole 10 mg in the second-line regimens. The eradication of H. pylori was assessed by the H. pylori stool antigen test. The overall first-line eradication rate with VPZ was significantly higher than that with LPZ [91.0% (250/275) vs. 84.7% (211/249), respectively, P=0.030]. The dose of CAM (400 vs. 800 mg) did not affect the eradication rate in either the VPZ or LPZ regimens. The overall eradication rates of the second-line regimens with MTZ did not differ significantly between the VPZ-failure and LPZ-failure groups [87.0% (20/23) vs. 87.9% (29/33), respectively, P= 0.700]. Therefore, VPZ was significantly more effective than LPZ for first-line treatment. In patients with failure of first-line eradication therapy, successful results of second-line eradication therapy did not differ between the VPZ-and LPZ-failure groups. In conclusion, VPZ-based triple therapy should be recommended for eradication of H. pylori.

show abstract

Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

Cited by 146 publications

References 32 publications

Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects

Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects

Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis

Second‑line triple therapy in failures with vonoprazan‑based triple therapy for eradication of Helicobacter pylori

Contact Info

Product

Resources

About